Natera (NASDAQ:NTRA) Price Target Cut to $160.00 by Analysts at Barclays

Natera (NASDAQ:NTRA) had its price objective reduced by Barclays from $200.00 to $160.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

NTRA has been the subject of a number of other research reports. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Morgan Stanley raised their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Finally, Guggenheim boosted their price target on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.76.

Natera Stock Up 3.3 %

Shares of Natera stock opened at $148.04 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera has a 52-week low of $83.13 and a 52-week high of $183.00. The company’s 50 day moving average price is $152.66 and its 200-day moving average price is $152.05. The stock has a market capitalization of $20.01 billion, a price-to-earnings ratio of -84.11 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Equities research analysts forecast that Natera will post -1.49 EPS for the current year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the transaction, the insider now owns 141,782 shares of the company’s stock, valued at $19,917,535.36. The trade was a 2.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,433,183.76. The trade was a 29.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 325,922 shares of company stock valued at $51,603,664 in the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NTRA. LRI Investments LLC purchased a new stake in shares of Natera during the fourth quarter valued at approximately $29,000. Blue Trust Inc. lifted its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc boosted its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Principal Securities Inc. raised its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.